Bristol-Myers Squibb debuted at the 5th CIIE with 12 global innovations

Shanghai, China, November 6, 2022 – On the occasion of its 40th anniversary in China, Bristol-Myers Squibb has returned to CIBO with the company's "China 2030 Strategy" with
the theme of "'Protecting Life'" 。 On a 900-square-meter booth in the Medical Devices & Healthcare exhibition area, Bristol-Myers Squibb comprehensively displayed 12 globally approved and research-pending innovative products or indications in core disease areas such as oncology, hematology and immunology, and successfully held the 40th anniversary celebration ceremony of "Rooted in China, Leading Innovation" to highlight the company's development history and strong commitment
to resonating with the Chinese market and empathizing with Chinese patients.

Bristol-Myers Squibb booth at the 5th CIIE

"The Chinese market is an important growth engine
for Bristol-Myers Squibb's global business.
40 years of perseverance and the China 2030 Strategy are our firm commitment to
the Chinese market.
" Bristol-Myers Squibb Chairman and CEO Dr.
Giovanni Caforio, M.
D.
"Bristol-Myers Squibb has witnessed the rapid changes in the Chinese market over the past 40 years, and is pleased to see China further open to
the outside world.
We look forward to working hand in hand with the Chinese government and partners from all walks of life to promote innovation and development
.
" ”

Accelerate the promotion of the "China 2030 Strategy" and take care of Chinese patients with innovative results

Bristol-Myers Squibb entered China in 1982 and established the first Sino-US joint venture pharmaceutical enterprise
after China's reform and opening up.
At the 40th anniversary ceremony held during CIIE, Bristol-Myers Squibb, together with government representatives, pharmaceutical economists, medical experts and partners, reviewed and looked forward to the path of innovation rooted in China – thanks to the Chinese government's support for innovation and long-term planning, Bristol-Myers Squibb has brought more than 40 innovative treatment options
to Chinese patients over the past 40 years 。 In order to make global innovation reach more Chinese patients faster, Bristol-Myers Squibb launched the "China 2030 Strategy" in 2020, making a long-term commitment to China's healthcare and innovation, aiming to accelerate the introduction of nearly 30 innovative products or indications around the world by 2025, while ensuring that phase III clinical studies are carried out simultaneously with the world and gradually participating in the early development of the world, and from 2026 to 2030, Bristol-Myers Squibb will accelerate the introduction of more global innovations.
Committed to becoming an innovation leader
in core therapeutic areas such as oncology, hematology and immunology in China.

Luo Zhisong, chief economist of Shanghai Municipal Commission of Commerce

On behalf of the Shanghai Municipal Commission of Commerce, Bristol-Myers Squibb was presented with a congratulatory plaque on the "40th Anniversary of Rooted in China"

At the Expo, Bristol-Myers Squibb brought 12 innovative products or indications
in three core disease areas.
In oncology, Bristol-Myers Squibb showcased several emerging immune checkpoint inhibitors
that have been shown to benefit patients.
Among them, the world's first anti-LAG-3 immune combination preparation Opdualag (nivolumab combined with relatlimab-rmbw) debuted in China
through this Expo.
The LAG-3 immune checkpoint inhibitor is the third Bristol-Myers Squibb immune checkpoint inhibitor
to be proven to benefit patients, after PD-1 inhibitors and CTLA-4 inhibitors.
Currently, Bristol-Myers Squibb is the only biopharmaceutical company
in the world that has launched three immune checkpoint inhibitors.

In the field of hematology, Bristol-Myers Squibb has brought global innovations such as liblozer (rotercept), oral azacitidine, fedratinib, iberdomide, mezigdomide and so on
.
Among them, the world's first and currently only red blood cell maturation agent Liblotzer is Bristol-Myers Squibb's first innovative product to "run" into China after participating in the last CIIE, bringing new treatment options to patients with β-thalassemia, which is expected to reduce the burden of blood transfusion and the risk of iron overload and complications caused by blood transfusion, and also bring positive social significance
to alleviate blood source tension.
At this CIIE, Liblozer's more globally approved and investigational indications will "premiere" in China, including myelodysplastic tumors, myelofibrosis and α-thalassemia
.

In the field of immunology, Bristol-Myers Squibb exhibited ozanimod, the world's first highly selective S1P receptor modulator approved by the US Food and Drug Administration (FDA) for the treatment of multiple sclerosis and ulcerative colitis, and the world's first FDA-approved oral, highly selective tyrosine kinase 2 (TYK2) allosteric inhibitor deucravacitinib
for the treatment of moderate to severe plaque psoriasis 。 The results of deucravacitinib's first multicenter phase III clinical study of psoriasis in Asia, mainly Chinese patients, were also exhibited
at the Expo.

"Over the past four decades, China's pharmaceutical and health industry has boomed
.
In recent years, the Chinese government's policies and measures in accelerating the regulatory process of new drug review and approval, initiating medical insurance reform, and strengthening intellectual property protection have further pointed out the direction for the innovation and development of the industry, and also provided huge development opportunities
for innovation-driven multinational biopharmaceutical companies.
"Looking ahead, we will continue to accelerate the 'China 2030 Strategy', introduce global innovation achievements to China, promote Chinese innovation to the world, and strive to become an innovation leader
'rooted in China and originating in China'.
" At the same time, we also look forward to working with more partners through the Expo to protect life with science and innovation
.
" ”

Explore the human universe in depth, and interpret the protection of "hand care" life with innovative technology

In addition to showcasing a rich and robust R&D pipeline and innovation achievements, Bristol-Myers Squibb also comprehensively presented the company's "China 2030 Strategy" through glasses-free 3D and augmented reality (AR) technology, demonstrating its exploration and commitment
to "hand care" life with innovative technology.

In 2020, Bristol-Myers Squibb sent biologics into space to carry out advanced research in life sciences in zero gravity and explore the future of
the human universe in the celestial universe.
Inspired by this cutting-edge exploration, Bristol-Myers Squibb integrated "cosmic gravitational waves" into the booth design of this year's CIIE, interpreting the possibility of exploring the living universe and representing the power
of transmitting "hand protection" life protection.
In addition, Bristol-Myers Squibb also pioneered the use of data audibility (Sonification) + AI intelligent algorithm composition, focusing on the theme of oncology, hematology, and immunology, bringing the audience the sound of
the human universe.